Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase 2 trial

BACKGROUND: We performed a phase II trial of pembrolizumab in patients with NSCLC or melanoma with untreated brain metastases to determine the activity of PD-1 blockade in the CNS. Interim results were previously published, and we now report an updated analysis of the full NSCLC cohort. METHODS: Thi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Goldberg, Sarah B., Schalper, Kurt A., Gettinger, Scott N., Mahajan, Amit, Herbst, Roy S., Chiang, Anne C., Lilenbaum, Rogerio, Wilson, Frederick H., Omay, Sacit Bulent, Yu, James, Jilaveanu, Lucia, Tran, Thuy, Pavlik, Kira, Rowen, Elin, Gerrish, Heather, Komlo, Annette, Gupta, Richa, Wyatt, Hailey, Ribeiro, Matthew, Kluger, Yuval, Zhou, Geyu, Wei, Wei, Chiang, Veronica, Kluger, Harriet M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7380514/
https://ncbi.nlm.nih.gov/pubmed/32251621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30111-X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados